Your FUT2 gene is the master switch for secretor status¹¹ secretor status
Whether you express ABO blood group antigens on mucosal surfaces and in saliva, tears, and intestinal mucus — a trait that fundamentally shapes your gut microbiome and immune landscape. rs492602 is a synonymous proxy variant that tags this biological divide: the G allele travels with the secretor phenotype, while the A allele travels with the non-secretor phenotype that arises from the nearby W143X nonsense mutation²² W143X nonsense mutation
rs601338 (G428A) creates a premature stop codon at amino acid 143 of FUT2, producing a truncated, non-functional enzyme; this is the primary FUT2 non-secretor variant in Europeans and Africans (rs601338). Although rs492602 itself is a silent coding change (alanine-68 codon remains alanine), it serves as a reliable genomic proxy for the functional variant in most populations.

The platform already tracks rs601338 in the vitamins-nutrients category, where the focus is on B12 absorption. This entry covers the orthogonal angle: the gut-skin axis³³ gut-skin axis
The bidirectional communication between the intestinal microbiome and skin immune function, increasingly recognised as a driver of inflammatory skin diseases including psoriasis and autoimmune susceptibility that rs492602 tags independently. The two entries address distinct clinical implications of the same underlying biology.

The Mechanism

FUT2 encodes alpha(1,2)-fucosyltransferase⁴⁴ alpha(1,2)-fucosyltransferase
An enzyme that adds the six-carbon sugar fucose to glycan chains on the surface of intestinal epithelial cells and into secreted mucus, creating the H antigen on which A and B blood group specificities are built. In secretors, fucosylated glycans line the gut wall and are shed into the intestinal lumen where they serve two purposes: attachment scaffolds for certain pathogens (and therefore pathogen resistance signals) and a dedicated carbon source for Bifidobacterium⁵⁵ Bifidobacterium
A genus of beneficial gut bacteria that have evolved specialised fucosidase enzymes to harvest fucose from host glycans as their primary food source in the gut species that have co-evolved with human secretors.

Non-secretors produce no functional FUT2 enzyme and therefore no mucosal fucosylated glycans. The immediate consequence is a profoundly altered intestinal microbiome — reduced Bifidobacterium richness and diversity, and an enrichment of bacteria that drive Th17-promoting inflammation. The gut of a non-secretor is structurally predisposed to a different immunological state from birth.

The Evidence

The secretor-microbiome connection was firmly established by Wacklin et al. 2011⁶⁶ Wacklin et al. 2011
Wacklin P et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One, 2011: in 71 healthy volunteers, non-secretors showed significantly reduced bifidobacterial richness (p<0.0001) and several key species (B. bifidum, B. adolescentis, B. catenulatum) were absent or rare in non-secretors but common in secretors.

The link between FUT2 non-secretor status and Crohn's disease was established by a genome-wide association study in 4,100 Caucasian participants⁷⁷ 4,100 Caucasian participants
McGovern DPB et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet, 2010 reaching genome-wide significance (P=4.90×10⁻⁸). Mechanistically, Tong et al. 2014⁸⁸ Tong et al. 2014
Tong M et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J, 2014 demonstrated that the non-secretor microbiome shows depleted amino-acid biosynthesis and enriched carbohydrate catabolism pathways, accompanied by sub-clinical mucosal inflammation in non-secretors even before disease onset.

The psoriasis association was identified in a Han Chinese case-control study Liu et al. 2021⁹⁹ Liu et al. 2021
Liu Y et al. Association of Polymorphisms of Metabolism-Related Genes with Psoriasis Vulgaris in Han Chinese. Biomed Res Int, 2021 of 1,030 psoriasis patients and 965 controls (OR=1.86, P=0.005). The association was stronger in individuals without the HLA-C*06:02 allele (OR=2.04), suggesting rs492602 contributes to psoriasis risk through a pathway partially independent of the canonical HLA-driven pathway. This is consistent with the gut-skin axis hypothesis: altered microbial composition drives systemic immune dysregulation that manifests in skin inflammation. Importantly, rs492602 sits in a genomic region with documented shared susceptibility for both psoriasis and Crohn's disease, supporting a common gut-immune mechanism.

A large Dutch microbiome GWAS Lopera-Maya et al. 2022¹⁰¹⁰ Lopera-Maya et al. 2022
Lopera-Maya EA et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat Genet, 2022 confirmed FUT2/secretor status as one of only two robust genome-wide significant genetic determinants of gut microbial composition, with a p-value below 1.89×10⁻¹⁰ — placing this among the most reproducible host-microbiome genetic associations in the human genome.

LD with rs601338: rs492602 is in strong LD with the functional W143X nonsense variant (rs601338) in European and African populations. The two variants are highly correlated, which is why rs492602 served as the GWAS tag SNP for B12 levels in the original Hazra et al. 2008 discovery. In East Asian populations, both variants are rare; the primary non-secretor allele there is rs1047781 (A385T). This entry focuses on the autoimmune and gut-skin axis biology; see the rs601338 entry for B12 absorption details.

Practical Actions

For non-secretors (AA), the gut-immune implications are the most actionable aspect of this variant. Supporting microbial diversity through prebiotic-rich foods and targeted Bifidobacterium probiotics can partially compensate for the structural deficit in mucosal glycan availability. Monitoring for early signs of gut inflammation is warranted given the elevated Crohn's risk.

For psoriasis specifically, the gut-skin axis implication means that gut microbiome health strategies may have downstream benefit for skin inflammation — though direct clinical evidence for probiotics modifying psoriasis severity in non-secretors specifically is not yet available.

Interactions

This variant is in strong LD with rs601338 (FUT2 W143X), which is separately catalogued for B12 metabolism. If you carry the A allele at rs492602, you very likely also carry the A (non-secretor) allele at rs601338. The two entries address different clinical angles of the same biology.

rs602662 (FUT2 S258G) is also in LD with this locus and shows similar Crohn's disease associations. In East Asian populations, rs1047781 (A385T) is the primary secretor-status determinant and should be checked in that ancestry context.

Von Willebrand factor is the molecular glue of hemostasis: a multimeric glycoprotein that captures platelets at the site of a vascular injury and shuttles factor VIII through the bloodstream. Without adequate VWF activity, even minor cuts fail to clot properly and surgical bleeding can become life-threatening. The rs61750630 variant — encoding the C2362F substitution¹¹ C2362F substitution
cysteine-to-phenylalanine change in the D4 domain of VWF — is a pathogenic missense change that disrupts protein folding in the endoplasmic reticulum, preventing most of the mutant protein from ever reaching the bloodstream. It was first identified as a founder mutation in northern Italian families with type 3 von Willebrand disease²² founder mutation in northern Italian families with type 3 von Willebrand disease
autosomal recessive severe VWD with near-absent VWF.

The Mechanism

VWF contains a series of cysteine-rich domains that form disulfide bonds critical for proper multimerization and secretion³³ disulfide bonds critical for proper multimerization and secretion
loss of a cysteine removes one bond from an intricate disulfide network. The Cys2362Phe substitution eliminates a cysteine in the D4 domain, disrupting the local disulfide architecture. The misfolded protein is retained in the endoplasmic reticulum rather than trafficked to the Golgi and secreted. Tjernberg et al. showed that cells expressing only VWF-C2362F secrete just 8% of normal VWF antigen levels⁴⁴ Tjernberg et al. showed that cells expressing only VWF-C2362F secrete just 8% of normal VWF antigen levels
compared to wild-type controls. Crucially, it is the loss of the cysteine itself — not the bulky phenylalanine side chain — that causes retention, since the same group showed the defect is structural rather than steric. When mutant and wild-type constructs are co-expressed (mimicking the heterozygous state), secretion reaches approximately 50% of normal, consistent with the mildly reduced VWF levels observed in carriers.

A further complication emerges upon desmopressin (DDAVP) stimulation: although homozygous patients do release some VWF in response to DDAVP, the mutant protein has a 2-fold shortened plasma half-life⁵⁵ 2-fold shortened plasma half-life
suggesting impaired interactions with ADAMTS13 or stabilizing proteins, making DDAVP a poor treatment option for severely affected patients.

The Evidence

Eikenboom et al. characterised eight northern Italian families with recessive VWD⁶⁶ Eikenboom et al. characterised eight northern Italian families with recessive VWD
identifying mutations in 14 of 16 disease-associated VWF alleles. The C2362F substitution appeared in every type 3 VWD patient from a subgroup previously noted for an unusually strong factor VIII response to desmopressin — a clinical phenotype that correlates with the founder haplotype. Haplotype analysis supported a single ancestral origin, making this one of the clearest examples of a VWF founder effect in a defined European population.

The inheritance picture is more nuanced than purely recessive. Bowman et al. studied 34 Canadian families with 31 distinct VWD type 3 mutations⁷⁷ Bowman et al. studied 34 Canadian families with 31 distinct VWD type 3 mutations
including C2362F carriers and found that in approximately half of families, heterozygous parents had bleeding symptoms and reduced VWF levels sufficient to diagnose type 1 VWD — evidence of co-dominant inheritance rather than a purely silent carrier state⁸⁸ co-dominant inheritance rather than a purely silent carrier state
48% of obligate carriers received a clinical VWD diagnosis. This means the risk_allele does not recede invisibly in the heterozygous state.

Given the global allele frequency of approximately 3.4 per million chromosomes in Europeans (gnomAD v4, n = 1,400,916 exomes), the C2362F variant is extremely rare outside of the northern Italian founder population. Homozygosity is essentially unique to that ancestry.

Practical Actions

For heterozygous carriers, the key step is a formal bleeding assessment: measure VWF antigen, VWF activity (ristocetin cofactor), and factor VIII. Levels around 50% of normal are typical; values below 30 IU/dL meet the diagnostic threshold for type 1 VWD and should trigger referral to a haematologist. Carriers should disclose their genetic status before any surgical procedure, dental extraction, or childbirth so a proactive haemostasis plan can be put in place.

For the rare homozygous individual, management follows type 3 VWD guidelines: plasma-derived or recombinant VWF concentrate (Vonvendi, Wilate, Humate-P) is the mainstay of treatment. DDAVP is not effective in type 3 VWD — VWF stores are severely depleted and the small amount released is cleared too rapidly to provide sustained haemostasis. All family members should be offered VWF screening.

Interactions

Carriers of two VWF null alleles (different mutations in trans, i.e. compound heterozygotes) present identically to homozygotes clinically. ABO blood group independently modulates VWF antigen levels — blood group O reduces VWF by approximately 25%, which can compound the haemostatic deficit in carriers who also have blood group O. Concurrent thrombocytopenia or platelet function defects (e.g. variants in GP1BA encoding the VWF receptor, or TBXA2R affecting platelet activation) can further worsen bleeding in VWF-deficient individuals.

PERK (EIF2AK3) is one of three master sensors of the endoplasmic reticulum stress response. When misfolded proteins accumulate in the ER — driven by inflammatory signals, hypoxia, or oxidative damage — PERK phosphorylates eIF2α to temporarily halt protein synthesis while activating selective transcription factors that coordinate cell survival or death. This unfolded protein response (UPR) is a double-edged switch: short-term PERK activation is cytoprotective, but chronic activation shifts cells toward apoptosis.

rs6757908 is a rare intronic variant in EIF2AK3-AS1, an antisense long non-coding RNA transcribed across the EIF2AK3 locus on chromosome 2. Antisense lncRNAs commonly regulate their sense-strand gene through chromatin remodeling, transcriptional interference, or post-transcriptional mechanisms. EIF2AK3-AS1 may therefore influence PERK expression or splicing — though the specific function of this lncRNA and any effect of rs6757908 on it have not yet been characterized experimentally.

Important note on gene attribution: This SNP's task brief described it as a GREB1 variant. This is incorrect: rs6757908 maps to chromosome 2 position 88,511,708 (GRCh38), which lies within EIF2AK3-AS1. The GREB1 gene occupies chromosome 2 positions 11,482,888– 11,642,788 — approximately 77 Mb upstream. The canonical GREB1 endometriosis locus is rs13394619, which is catalogued separately. This entry addresses rs6757908 on its own genomic and biological merits.

The Mechanism

The peritoneal microenvironment in endometriosis is rich with pro-inflammatory cytokines, reactive oxygen species, and hypoxic signals — all potent inducers of ER stress. In this setting, phospho-PERK is elevated in ectopic glandular and stromal cells, particularly during the late proliferative phase¹¹ phospho-PERK is elevated in ectopic glandular and stromal cells, particularly during the late proliferative phase
Ekiz-Yilmaz et al. Reproductive Biomedicine Online, 2021. Peritoneal fluid from women with endometriosis rapidly increases p-PERK and p-IRE1 levels in normal endometrial stromal cells within 10–60 minutes of exposure — indicating that the disease environment actively induces ER stress in adjacent tissue.

In the ovary, granulosa cells from endometrioma-affected follicles show elevated phospho-PERK, phospho-IRE1, and UPR-associated mRNAs²² granulosa cells from endometrioma-affected follicles show elevated phospho-PERK, phospho-IRE1, and UPR-associated mRNAs
Kunitomi et al. Molecular Human Reproduction, 2020. ER stress-mediated apoptosis of granulosa cells is a likely mechanism by which endometriosis reduces ovarian reserve — connecting the PERK pathway to the fertility consequences of the disease, not just to lesion biology.

That the PERK axis is functionally relevant to endometriosis is reinforced by therapeutic experiments: inducing ER stress pharmacologically via chrysin activates the GRP78-PERK-eIF2α pathway and drives preferential apoptosis of endometriotic cells³³ inducing ER stress pharmacologically via chrysin activates the GRP78-PERK-eIF2α pathway and drives preferential apoptosis of endometriotic cells
Ryu et al. Journal of Cellular Physiology, 2019, establishing PERK modulation as a candidate therapeutic target in the disease.

EIF2AK3-AS1 antisense transcription across the PERK gene could theoretically tune EIF2AK3 expression level — and thereby the threshold at which ER stress triggers survival versus death in ectopic endometrial cells. Whether rs6757908 alters this regulatory function is unknown; no functional studies of this specific variant have been published.

The Evidence

rs6757908 itself has no published GWAS associations in any major catalog (EBI GWAS Catalog, ClinVar, dbSNP publications list). No PubMed papers index this rsid. Its G allele is extremely rare: approximately 0.9% globally, essentially absent in Europeans (~0.1%) and East Asians (~0%), and most frequent in individuals of African ancestry (~3.5%). The extreme rarity makes GWAS discovery statistically near-impossible with current cohort sizes.

The evidence linking this variant to endometriosis is therefore entirely inferential — resting on pathway biology (PERK is activated in endometriotic tissue; EIF2AK3-AS1 may regulate EIF2AK3 expression; this variant lies within EIF2AK3-AS1) rather than direct genetic association. Evidence level: emerging.

Practical Implications

Given the complete absence of direct genetic evidence, clinical interpretation must be cautious. Heterozygous AG carriers hold one copy of a rare variant near a gene whose protein is activated in endometriotic tissue. This biological context warrants symptom vigilance without elevating concern beyond what the evidence supports. The most defensible approach is to use this result alongside the well-validated endometriosis loci in the genetic profile rather than interpreting it in isolation.

Interactions

rs13394619 (GREB1): The canonical GREB1/2p25.1 endometriosis locus operates through estrogen-driven GREB1 amplification of ectopic tissue proliferation — a distinct pathway from PERK-mediated ER stress. Both estrogen signaling and ER stress converge on ectopic lesion survival, but through independent mechanisms. No formal interaction has been studied between these loci, and no compound action is proposed at this evidence level.

Psoriasis is not a single disease — it is a spectrum. About 2-3% of people develop psoriasis at some point in their lives, and in roughly 25-30% of them, the inflammation extends beyond the skin to attack the joints, a condition called psoriatic arthritis¹¹ psoriatic arthritis
A chronic inflammatory arthritis affecting peripheral joints, the spine, entheses (tendon/ligament insertions), and nails. Untreated PsA causes irreversible joint erosion and ankylosis within 2 years in a significant fraction of patients (PsA). Identifying which psoriasis patients are heading toward joint disease — ideally before the first erosion appears on X-ray — is one of the central unmet needs in dermatology and rheumatology. rs7152376, a regulatory variant near the NFKBIA gene, is one of the clearest genetic markers currently known for that distinction.

The Mechanism

NFKBIA encodes IκB-alpha²² IκB-alpha
IκB-alpha (Inhibitor of kappa B alpha) is the primary cytoplasmic brake on NF-κB. It physically binds the NF-κB p65/p50 dimer and sequesters it in the cytoplasm. Pro-inflammatory signals (TNF, IL-1, TLR ligands) trigger IκB-alpha phosphorylation and proteasomal degradation, releasing NF-κB to translocate to the nucleus and activate cytokine gene transcription. Once NF-κB has driven its target genes, a feedback mechanism induces fresh NFKBIA transcription to reset the system. Variants impairing this feedback allow NF-κB to remain constitutively active in inflamed tissue, the principal cytoplasmic inhibitor of NF-κB signaling. NFKBIA sits on the minus strand of chromosome 14, with rs7152376 located approximately 17.7 kb upstream in genomic coordinates — a position that corresponds to the 5' regulatory region of the gene in the direction of NFKBIA transcription. Though not within the coding sequence, the variant lies in a region consistent with enhancer or chromatin-accessibility regulation of NFKBIA expression.

Reduced IκB-alpha expression or function allows NF-κB dimers to persist in the nucleus, sustaining transcription of TNF-alpha, IL-1beta, IL-6, IL-17, and IL-23 — the cytokines that drive both synovial hyperplasia and joint erosion in PsA. The specific consequence of C-allele carriage at rs7152376 for NFKBIA transcription has not been directly characterized in reporter assays, but a 2025 single-cell RNA sequencing study³³ 2025 single-cell RNA sequencing study
Garrido et al. Single-cell RNA sequencing of circulating immune cells supports inhibition of TNFAIP3 and NFKBIA translation as psoriatic arthritis biomarkers. Frontiers in Immunology 2025 provides a mechanistic clue: NFKBIA mRNA is paradoxically overexpressed in PsA immune cells compared to cutaneous-only psoriasis, yet IκBα protein is reduced in PsA CD8+ T cells — suggesting that translational suppression, rather than transcriptional silencing, is the operative mechanism. The rs7152376 C allele may tag a haplotype that contributes to this translational inefficiency in synovial immune compartments.

The Evidence

The primary association evidence comes from a Spanish case-control study⁴⁴ Spanish case-control study
Coto-Segura P et al. Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease. Biomed Res Int 2019 enrolling 690 psoriatic disease patients and 550 healthy controls from a Northern Spanish cohort. The rare C allele of rs7152376 was significantly enriched in PsA patients compared to both healthy controls (OR=2.03, 95% CI 1.3-3.1, p<0.01) and compared to pure cutaneous psoriasis patients (OR=3.2, 95% CI 2.1-5.1, p<0.001). The 3.2-fold odds ratio for PsA versus cutaneous psoriasis is the more clinically informative figure — it is not simply that C-allele carriers are more likely to have psoriasis in general, but specifically that among people with psoriasis, C-allele carriers are far more likely to develop joint involvement.

This finding is consistent with the broader NFKBIA locus biology established by the Stuart et al. GWAS⁵⁵ Stuart et al. GWAS
Stuart PE et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet 2015 of 3,061 PsA patients, 3,110 cutaneous psoriasis patients, and 13,670 controls in European ancestry, which confirmed NFKBIA as achieving genome-wide significance independently for both PsA and PsC, with the two subtypes showing partially distinct genetic architecture. NFKBIA is not merely a general psoriasis susceptibility gene — it is a locus where different regulatory variants specifically determine the trajectory toward joint versus skin-limited disease.

The evidence base for rs7152376 specifically is currently limited to a single European cohort study, hence the moderate evidence rating. No independent replication has been published for this exact variant, though the locus-level association is well-established. A companion variant in the same regulatory region, rs12883343, was independently identified as a PsA-specific marker in a Chinese cohort (OR=2.371 for PsA vs cutaneous psoriasis, p=4.93×10⁻¹⁰), reinforcing that NFKBIA regulatory variation tracks joint involvement across populations.

Practical Actions

For C-allele carriers with psoriasis, the actionable implication is heightened clinical vigilance for early PsA features: dactylitis⁶⁶ dactylitis
"Sausage digit" — fusiform swelling of an entire finger or toe, caused by simultaneous flexor tendon sheath inflammation and small joint synovitis. Often painless in early stages. Highly specific for PsA when it occurs in a person with psoriasis, [enthesitis | Inflammation at the site where tendons and ligaments insert into bone. The Achilles insertion, plantar fascia, and patellar tendon are the most common sites. Causes tenderness on direct pressure that most people attribute to overuse], and asymmetric peripheral joint inflammation. Early DMARD or biologic therapy started before radiographic erosion significantly improves long-term outcomes.

NF-κB pathway activity can be modulated through documented nutritional interventions: high-dose omega-3 fatty acids suppress NF-κB through GPR120 and PPARγ pathways, and vitamin D receptor activation directly induces NFKBIA transcription in immune cells. Both represent evidence-based strategies to partially compensate for impaired IκB-alpha function at this locus.

Interactions

rs7152376 and the companion NFKBIA regulatory variant rs12883343 were identified in different population cohorts (European and Chinese, respectively) and likely tag distinct but overlapping regulatory haplotypes at the same locus. They are not in perfect linkage disequilibrium and may represent partially independent functional signals within the NFKBIA regulatory region.

TNFAIP3 (A20), tagged by rs9321623 and rs5029937, is the other principal NF-κB negative regulator in psoriatic disease. A20 acts upstream of IκB-alpha by deubiquitinating TRAF6 and RIPK1, thereby limiting NF-κB activation before it reaches the IκB-alpha degradation step. Individuals carrying risk alleles at both NFKBIA and TNFAIP3 loci impair NF-κB suppression through two independent mechanisms, a combination that may define a high-risk PsA subgroup.

IL-23R (tagged by rs12044149) contributes PsA-specific risk through the Th17 axis, which is partially NF-κB-dependent. Convergence of NFKBIA regulatory impairment with IL-23R susceptibility alleles may identify patients most likely to benefit from early IL-17 or IL-23 inhibitor therapy.

Your immune system must learn to attack pathogens without attacking your own tissues — a balancing act that starts in the thymus, where T cells are educated and self-reactive cells are eliminated. CLEC16A encodes an E3 ubiquitin ligase that controls autophagy¹¹ autophagy
the cellular recycling process that breaks down damaged proteins and organelles in thymic epithelial cells. Variants in this gene alter how effectively the thymus presents self-antigens to developing T cells — and a less effective thymic curriculum graduates more self-reactive T cells that can later attack the body's own tissues. rs725613 is one of three intronic CLEC16A variants in strong linkage disequilibrium²² linkage disequilibrium
correlated alleles inherited together as a block, so they tag the same underlying signal that have been associated with both type 1 diabetes and multiple sclerosis.

The Mechanism

CLEC16A sits within a critical gene cluster on chromosome 16p13 alongside CIITA, DEXI, and SOCS1 — genes governing immune cell differentiation and cytokine signaling. The rs725613 variant and its LD partners act as expression quantitative trait loci³³ expression quantitative trait loci
genetic variants that affect how much of a gene's mRNA is produced, rather than changing the protein sequence itself: risk allele carriers show altered CLEC16A and SOCS1 expression specifically in thymic tissue and CD4+ T cells.

The biological consequence flows through autophagy. Thymic epithelial cells (TECs) use autophagy to process and present self-antigens to developing T cells during negative selection — the process that eliminates T cells capable of attacking the body. Reducing CLEC16A expression⁴⁴ Reducing CLEC16A expression
Mouse models with reduced Clec16a in thymic epithelium produced T cells with lower autoreactivity and were protected against T1D impairs TEC autophagy, which alters the self-antigen repertoire presented to thymocytes. The result is subtly altered T-cell selection — the thymus graduates T cells with a slightly different reactivity profile, with some studies suggesting higher overall SOCS1 expression in T cells that may paradoxically affect cytokine signaling downstream.

The variant also influences CLEC16A expression in pancreatic β-cells⁵⁵ pancreatic β-cells
the insulin-producing cells destroyed in type 1 diabetes, where CLEC16A maintains mitochondrial quality control through mitophagy. Impaired mitophagy in β-cells leads to mitochondrial dysfunction and compromised insulin secretion, potentially contributing to T1D pathogenesis through a second, peripheral mechanism independent of T-cell selection.

The Evidence

The rs725613 signal was discovered in a genome-wide association study of Northern European T1D patients and replicated across populations. A Sardinian cohort study⁶⁶ Sardinian cohort study
Zoledziewska et al., Genes & Immunity, 2009 — rs725613 allele A associated with T1D (OR 1.15) and MS (OR 1.21) in 1,037 T1D cases, 1,498 MS cases, and 1,706 controls demonstrated that the same variant confers risk for both T1D and MS with comparable effect sizes — unusual evidence for a shared immunological pathway underlying two clinically distinct diseases.

Fine-mapping in a German MS cohort⁷⁷ Fine-mapping in a German MS cohort
Nischwitz et al., Acta Neurologica Scandinavica, 2011 — 31 CLEC16A SNPs genotyped in 603 MS patients and 825 controls; four intron-19 SNPs associated, rs725613 replicated confirmed rs725613 as a genuine MS risk signal and localized the effect to an ~50 kb linkage disequilibrium block within intron 19. A meta-analysis of 37 studies⁸⁸ meta-analysis of 37 studies
Tang et al., PLoS One, 2013 — 37,033 T1D cases and 54,716 controls; rs725613 G allele OR 0.71 (95% CI 0.55–0.92), p=0.01, classified as protective for T1D pooling 37,033 T1D cases confirmed the protective effect of the G allele (OR 0.71 for T1D), consistent across studies.

The G allele frequency varies markedly by ancestry: ~37% in Europeans, ~19% in East Asians, and ~59% in Africans. This population stratification helps explain why CLEC16A associations were initially discovered in European cohorts — East Asians carry fewer copies of the protective G allele and thus have a higher background rate of the risk-associated T allele at this locus.

CLEC16A variants have also been associated with at least 16 additional autoimmune conditions including systemic lupus erythematosus, celiac disease, Crohn's disease, and rheumatoid arthritis⁹⁹ systemic lupus erythematosus, celiac disease, Crohn's disease, and rheumatoid arthritis
Comprehensive review of CLEC16A function across autoimmune conditions including 18 GWAS-confirmed disease associations, underscoring the gene's broad role in immune tolerance across multiple tissues.

Practical Actions

The TT genotype (risk-allele homozygotes) carries modestly elevated odds for T1D (OR ~1.15–1.3 per allele dose) and MS (OR ~1.21 per allele dose). These are moderate effects in the context of multifactorial diseases — other genetic and environmental factors dominate absolute risk. The actionable insight is targeted monitoring: T1D and MS both have early biomarkers that enable earlier intervention when caught proactively.

For T1D, autoantibody screening (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin) can detect pre-clinical immune activation years before β-cell destruction becomes symptomatic. For MS, familiarity with early neurological symptoms — visual changes, numbness, weakness, balance problems — enables prompt MRI and neurological evaluation. Vitamin D insufficiency is a documented modifiable risk factor for both conditions; genotype-guided vitamin D optimization is a specific, actionable step for CLEC16A risk carriers.

Interactions

rs725613 is in strong LD with rs2903692 and rs17673553 — all three mark the same intronic 16p13 haplotype block. It is also in partial LD with rs12708716, an independent CLEC16A signal with documented thymic eQTL effects on SOCS1 and DEXI. Individuals carrying risk alleles at multiple CLEC16A variants across these LD blocks may have a larger overall effect on CLEC16A expression than any single variant predicts.

The chromosome 16p13 region includes SOCS1, an inhibitor of JAK-STAT cytokine signaling. Because CLEC16A risk variants affect SOCS1 expression in thymic tissue and T cells, interactions with cytokine pathway variants in IL2RA (rs2104286), PTPN22 (rs2476601), and HLA region variants likely modulate the net autoimmune risk — though no formal compound-genotype studies have quantified these combined effects for rs725613 specifically.

Your kidneys filter roughly 700 mg of uric acid per day, reabsorbing most of it through transporters in the proximal tubule before it reaches the urine. The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9, the primary high-capacity urate transporter on the basolateral membrane of proximal tubule cells; it mediates voltage-driven efflux of urate from tubular cells back into the bloodstream, and genetic variation across its approximately 46 kb genomic region accounts for 3–8% of serum urate variance in the population.

rs7679916 lies approximately 2 kilobases upstream of the SLC2A9 transcription start site — in the presumptive promoter region rather than within the gene's coding or intronic sequences. This positions it as a potential regulatory variant affecting how much GLUT9 protein the kidney produces, though the functional mechanism has not been directly demonstrated for this specific variant. It forms part of a high-LD haplotype block (r² > 0.9 among five nearby SNPs) in the upstream region, suggesting these variants are co-inherited and likely tag the same biological signal (Li et al., 2012)²² (Li et al., 2012).

The Mechanism

Because rs7679916 sits upstream of the SLC2A9 coding sequence, it is thought to influence urate handling through transcriptional regulation rather than by changing the GLUT9 protein structure. Variants in presumptive promoter regions can alter transcription factor binding sites: for example, a neighbouring upstream SNP (rs13124007) was found to disrupt a binding site for interferon regulatory factor 1 (IRF-1), potentially reducing SLC2A9 expression. If rs7679916 similarly affects a regulatory element, the T allele may lead to higher GLUT9 expression or activity — increasing urate reabsorption from tubular fluid and raising steady-state serum uric acid levels. However, this mechanistic model is inferred from the genomic context and has not been confirmed by reporter assays or expression quantitative trait locus (eQTL) studies for this specific variant.

The SLC2A9 locus as a whole harbours multiple independent genetic signals for urate levels. rs7679916 represents a potential additional layer to the well-characterised coding signals (rs3733591 Arg265His, rs16890979 Val282Ile) and intronic signals (rs11942223), though whether it is truly independent or in partial LD with these established variants has not been formally tested.

The Evidence

Evidence for rs7679916 specifically is limited. A candidate-gene study of 1,053 hyperuricemia cases and 1,373 normouricemia controls in a Uygur population from Xinjiang, China examined five SLC2A9 SNPs in the upstream region. In the normouricemia subgroup, rs7679916 showed a marginal positive association with serum uric acid concentration (β = 5.77 ± 3.09 mg/dL per allele, P = 0.0626), and the companion upstream variant rs938557 reached significance (β = 11.39, P = 0.0024). Crucially, neither variant showed significant association with hyperuricemia status itself after controlling for age, gender, and BMI (Li et al., 2019)³³ (Li et al., 2019).

The broader promoter-region architecture was characterised by Li et al. (2012), who sequenced 21 SNPs in the ~2 kb upstream region in a Chinese male population and identified two SNPs (rs13124007 and rs6850166) significantly associated with gout (ORs of 1.71 and 1.65 respectively) — but rs7679916 itself was not among the significant hits in that study; it was in high LD with several nearby upstream variants (Li et al., 2012)⁴⁴ (Li et al., 2012).

This evidence base places rs7679916 at an emerging level: a biologically plausible position in the known SLC2A9 regulatory region, marginal association in one population, and no independent replication at the specific variant level.

Practical Actions

SLC2A9 variants as a class — including rs7679916 — point to the same management approach: reducing the purine and fructose inputs that generate uric acid, and supporting the renal machinery that clears it. The key dietary levers with evidence specific to GLUT9 function are:

Purines: Organ meats, shellfish, anchovies, and red meat are the highest-density purine sources. Purine-rich vegetables (spinach, mushrooms, asparagus) have a weaker effect on serum urate than animal purines and are not restricted in major guidelines.

Fructose: High-fructose corn syrup and concentrated fruit juice drive urate synthesis hepatically by depleting ATP and generating AMP, independent of renal transport. SLC2A9-mediated urate transport is facilitated by glucose and fructose — high sugar exposure can amplify urate load on the transporter.

Vitamin C: Vitamin C competitively inhibits urate reabsorption at the renal proximal tubule, providing a genotype-independent uricosuric effect at doses of 200–500 mg/day.

If serum uric acid is borderline or elevated, periodic measurement (every 1–2 years) allows tracking against the clinical threshold of 6.8 mg/dL, above which urate crystallises in joints and soft tissue.

Interactions

With rs11942223 (SLC2A9 intronic signal): rs11942223 is the best-characterised intronic signal at the SLC2A9 locus, explaining up to 6% of urate variance in women. It operates through a regulatory mechanism similar to what rs7679916 may represent. Whether these two upstream/intronic signals are in LD or independent has not been formally assessed — they may partially tag the same haplotype or represent distinct regulatory elements. Carrying risk alleles at both loci would plausibly compound the effect on GLUT9 expression and renal urate clearance.

With rs3733591 (SLC2A9 Arg265His) and rs16890979 (Val282Ile): These coding variants change the GLUT9 protein structure and thus the transporter's intrinsic urate-transport capacity. The upstream variant rs7679916 may act orthogonally — influencing how much transporter is produced rather than how efficiently it functions. Combined effects across regulatory and coding variants at SLC2A9 are additive in their impact on renal urate handling.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate secretion (gut efflux pathway). Any renal pathway variant including rs7679916 acts independently of ABCG2. Individuals carrying risk alleles at both rs7679916 and ABCG2 rs2231142 face elevated urate from both the renal reabsorption and intestinal secretion axes simultaneously.

At a single enzymatic step buried deep in the steroid hormone assembly line, 3β-hydroxysteroid dehydrogenase type II — encoded by HSD3B2 — performs one of the most consequential conversions in human biochemistry: it transforms inactive Δ5-steroids into the active Δ4-steroids that become cortisol, aldosterone, testosterone, and estrogen. 3β-HSD type II¹¹ 3β-HSD type II
The type II isoenzyme is the adrenal and gonadal form; HSD3B1 is a distinct gene expressed in placenta and peripheral tissues that cannot compensate for HSD3B2 loss in the adrenal or gonad. The Trp171X variant (c.512G>A, p.Trp171Ter) introduces a premature stop codon at codon 171, producing a severely truncated protein that lacks the final 202 amino acids — including the entire substrate-binding domain. No residual enzymatic activity remains.

The Mechanism

HSD3B2 catalyzes the oxidative conversion of Δ5-ene-3β-hydroxy steroids (pregnenolone, DHEA, 17α-hydroxypregnenolone, androstenediol) into their Δ4-ketone counterparts (progesterone, androstenedione, 17α-hydroxyprogesterone, testosterone). This single step is required at the entrance to every branch of steroid hormone synthesis in the adrenal cortex and gonads. When this step is blocked²² When this step is blocked
Without functional 3β-HSD type II, the adrenal glands can still produce cholesterol and cleave it to pregnenolone via StAR and CYP11A1, but the downstream cascade to cortisol, aldosterone, and sex steroids halts completely at the Δ5→Δ4 branch point.

The Trp171X nonsense mutation was first described by Simard et al. 1993³³ Simard et al. 1993
Molecular Endocrinology 7(5):716-28 in a compound heterozygous patient with severe salt-losing disease. Functional studies confirmed no detectable 3β-HSD enzymatic activity from the truncated allele. The GRCh38 plus-strand change (G→A at chr1:119,422,013) converts the TGG tryptophan codon to TAG (stop), verified against ClinVar VCV000012184 with "criteria provided, multiple submitters, no conflicts" review status — the highest non-expert-panel ClinVar tier.

The Evidence

3β-HSD2 deficiency (OMIM 201810) is among the rarest forms of congenital adrenal hyperplasia. The comprehensive mutation registry reviewed by Simard, Moisan & Morel 2002⁴⁴ Simard, Moisan & Morel 2002
Seminars in Reproductive Medicine catalogued 34 pathogenic HSD3B2 variants across 56 patients from 44 families — making it one of the smallest CAH gene mutation databases despite its clinical severity.

Two clinically distinct presentations emerge from the genotype-phenotype data:

• Salt-wasting form: Complete enzyme loss (nonsense, frameshift, large missense changes) produces the most severe phenotype. Neonatal salt-wasting crises occur within the first 2–4 weeks of life as aldosterone and cortisol fail. In 46,XY patients, incomplete masculinization occurs because testosterone synthesis in the fetal gonad is also abrogated. In 46,XX patients, mild virilization may paradoxically occur due to adrenal DHEA accumulation converted peripherally by HSD3B1.

• Non-salt-wasting form: Partial-activity missense mutations leave enough residual enzyme to prevent mineralocorticoid crisis but still cause incomplete androgen synthesis. These patients often present later — at puberty, or even in adulthood.

The diagnostic challenge is illustrated by Jeandron & Sahakitrungruang 2012⁵⁵ Jeandron & Sahakitrungruang 2012
Hormone Research in Paediatrics: a 46,XX newborn with a homozygous HSD3B2 nonsense mutation (Q334X) had elevated 17-hydroxyprogesterone on newborn screen and was initially diagnosed as 21-hydroxylase deficiency. The elevation occurs because peripheral HSD3B1 converts the accumulating 17α-hydroxypregnenolone to 17α-hydroxyprogesterone — mimicking 21-OHD biochemistry. Correct diagnosis requires HSD3B2 gene sequencing.

A late-diagnosed case reported by Fanis et al. 2020⁶⁶ Fanis et al. 2020
J Pediatr Endocrinol Metab illustrates the diagnostic fingerprint: GC-MS urinary steroid metabolome showing the characteristic accumulation of Δ5-steroid metabolites — the most reliable non-genetic diagnostic tool for 3β-HSD deficiency when gene sequencing is not immediately available.

Practical Actions

Treatment of classic salt-wasting 3β-HSD2 deficiency is analogous to other forms of CAH requiring both glucocorticoid and mineralocorticoid replacement. Hydrocortisone suppresses the chronically elevated ACTH, reducing substrate accumulation. Fludrocortisone replaces the absent aldosterone to normalize sodium and potassium balance. Androgen suppression in 3β-HSD2 deficiency is notably more difficult than in 21-hydroxylase deficiency because adrenal DHEA continues to accumulate and is converted peripherally.

For carriers — heterozygous individuals with one functional and one Trp171X allele — enzyme activity is approximately halved but clinically silent. The primary clinical relevance is reproductive: two carrier parents face a 25% probability of an affected child with each pregnancy. Newborn screening identifies affected neonates before salt-wasting crisis in most high-income countries, but rapid confirmatory testing is essential.

Interactions

HSD3B2 Trp171X interacts critically with compound heterozygous variants in the same gene. A single copy of Trp171X paired with any other HSD3B2 loss-of-function variant (frameshift, nonsense, or complete-loss missense) produces compound heterozygous disease clinically indistinguishable from homozygous disease. Simard et al. 1993 described exactly this pattern: W171X + E142K compound heterozygosity producing severe salt-wasting phenotype.

HSD3B2 Trp171X does not interact with variants in other steroidogenic genes (CYP21A2, CYP17A1, CYP11B1) in any documented compound heterozygous sense, as 3β-HSD2 deficiency is a discrete enzymatic block upstream of all other steroid synthesis steps.

Nitric oxide (NO) is the blood vessel's primary vasodilator — the molecule that keeps arteries relaxed, blood flowing smoothly, and blood pressure in check. GCH1 (GTP Cyclohydrolase 1)¹¹ GCH1 (GTP Cyclohydrolase 1)
the rate-limiting enzyme in tetrahydrobiopterin synthesis is a gatekeeper of NO production. Without adequate BH4 — the essential cofactor that keeps endothelial nitric oxide synthase (eNOS) in its productive, coupled state — eNOS stops making NO and starts making superoxide instead. This switch, called NOS uncoupling²² NOS uncoupling
when eNOS produces reactive oxygen species rather than NO, worsening both oxidative stress and vascular tone, is a central driver of hypertensive vascular disease. The rs841 variant in GCH1 tags individuals whose BH4 synthesis capacity is genetically constrained.

The Mechanism

rs841 sits in an intron of GCH1 on chromosome 14 (and also in the 3' UTR of one transcript variant), on the minus strand of the genome. Papers describe it using coding-strand notation as "C+243T" — where the T allele (corresponding to A on the plus strand, the allele reported in genome files) is the functional variant. GCH1 forms part of a two-haplotype-block structure in the gene; rs841 anchors one of these blocks alongside rs10483639 and rs3783641, collectively tagging a haplotype associated with reduced GCH1 expression or activity³³ haplotype associated with reduced GCH1 expression or activity
Wolkow et al. 2014: the same haplotype block drives both oxidative stress markers and endothelial function measures.

When GCH1 activity is reduced, BH4 supply to eNOS falls. Coupled eNOS transfers electrons from NADPH to L-arginine and produces NO. Uncoupled eNOS — lacking BH4 — transfers those electrons to molecular oxygen, producing superoxide instead. The superoxide then reacts with remaining NO to form peroxynitrite, which in turn oxidizes GTPCH1 itself (releasing zinc and inhibiting BH4 synthesis further), creating a feed-forward cycle of vascular dysfunction⁴⁴ feed-forward cycle of vascular dysfunction
Wu et al. 2021: peroxynitrite → GTPCH1 inhibition → less BH4 → more uncoupling → more peroxynitrite.

The Evidence

The strongest direct evidence for rs841 comes from a study of 117 type 2 diabetes patients (Wolkow et al., PLoS One 2014)⁵⁵ study of 117 type 2 diabetes patients (Wolkow et al., PLoS One 2014)
five GCH1 polymorphisms assessed across two haplotype blocks against endothelial and oxidative stress markers. Among the five SNPs, rs841 showed association with flow-mediated dilation (a standard endothelial function test; p=0.01), malondialdehyde levels (a lipid peroxidation marker; p=0.0015), and von Willebrand factor (an endothelial injury marker; p=0.03). These associations held within the context of multiple GCH1 polymorphisms in the same analysis, supporting that rs841 carries independent information about BH4-NO pathway function.

Mechanistic evidence from mouse genetics is compelling: endothelial-specific GCH1 deletion virtually abolished NO bioactivity, elevated superoxide production, and raised blood pressure⁶⁶ virtually abolished NO bioactivity, elevated superoxide production, and raised blood pressure
Chuaiphichai et al. Hypertension 2014; ex vivo BH4 analogue sepiapterin restored normal endothelial function. A 2026 follow-up using inducible endothelial Gch1 deletion revealed sex-specific dynamics⁷⁷ sex-specific dynamics
Chuaiphichai et al. Hypertension 2026: males showed progressive hypertension over 24 weeks; females showed earlier but non-progressive hypertension that worsened dramatically during pregnancy.

In a Chinese Han case-control study of 558 ischemic stroke patients and 557 controls, rs841 showed independent association with stroke risk (dominant model p=0.00006); combined with rs1049255 (another GCH1 variant), the risk genotype carried an OR of 1.73 (95% CI 1.27–2.35)⁸⁸ OR of 1.73 (95% CI 1.27–2.35)
Yan et al. Acta Pharmacol Sin 2011.

A protective signal also emerged in obstructive sleep apnea research⁹⁹ obstructive sleep apnea research
Sheikhi Kouhsar et al. Sci Rep 2019: 94 OSA patients and 100 controls, where the heterozygous GA genotype inversely associated with OSA severity (p=0.005) — consistent with the heterozygous state preserving partial BH4 production and maintaining vascular tone during intermittent hypoxia.

Practical Actions

For AA homozygotes, the GCH1 BH4 pathway is most constrained. Targeted strategies include BH4 precursor support via sapropterin or sepiapterin (prescription) and nutritional cofactor optimization. Riboflavin (B2) is required for GCH1 enzyme activity; folate in its active 5-MTHF form contributes to BH4 recycling through the dihydrobiopterin reductase pathway. L-arginine (the NOS substrate) optimization matters less than BH4 availability, since uncoupled eNOS cannot productively use L-arginine regardless of its concentration. Nitrate-rich vegetables (beetroot, spinach, arugula) provide an eNOS-independent NO source that remains functional even when BH4 is depleted.

Sex context matters: women with A-allele variants should be aware that the BH4-NO pathway becomes particularly important during pregnancy, where endothelial function is critical for uteroplacental blood flow.

Interactions

rs841 is in partial linkage disequilibrium with rs10483639, rs3783641, and rs8007267 — all within the GCH1 two-haplotype-block structure. Combined haplotype analyses consistently show stronger associations than individual SNPs. The GCH1 pathway interacts with eNOS (NOS3; rs1799983) — GCH1 variants determine BH4 availability while NOS3 variants affect eNOS expression and activity; combined risk genotypes are expected to compound NOS uncoupling further.

GCH1 variants also interact with the folate-methylation cycle: 5-MTHF is required to maintain BH4 in its reduced (active) form via the tetrahydrobiopterin recycling pathway. MTHFR variants (rs1801133) that reduce methylfolate availability therefore compound the BH4 deficiency risk in GCH1 A-allele carriers.

STAT6 (Signal Transducer and Activator of Transcription 6)¹¹ STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor activated by IL-4 and IL-13 signaling; when these cytokines bind their receptor, STAT6 becomes phosphorylated, dimerizes, and translocates to the nucleus to switch on genes for IgE production, eosinophil recruitment, and airway remodeling — the cellular signature of allergic disease sits at the center of the Th2 immune axis. The rs167769 variant is located in intron 2 of the STAT6 gene on chromosome 12q13, approximately 1,600 base pairs downstream of its haplotype partner rs324011. Together, these two intronic variants form a functional regulatory unit that controls how much STAT6 protein the cell produces in response to inflammatory signals.

The Mechanism

Deep sequencing of the STAT6 intron 2 regulatory region, published by Schedel et al. 2009²² Schedel et al. 2009
J Allergy Clin Immunol; identified rs167769 among intronic variants modulating STAT6 expression; T alleles of both rs324011 and rs167769 significantly increased STAT6 promoter activity in luciferase reporter assays, revealed that the T allele at rs167769, like the T allele at rs324011, significantly increases STAT6 promoter activity compared to the C allele. When both T alleles are present on the same chromosome — the rs167769-T / rs324011-T haplotype — the upregulation of STAT6 transcription is most pronounced. The precise mechanism for rs167769 is less fully characterized than for rs324011 (which creates a new NF-κB binding site), but the functional assay evidence for both SNPs acting in concert on STAT6 promoter activity is consistent and replicated.

The consequence of elevated STAT6 expression is amplified Th2 signaling downstream: more IgE class switching in B cells, enhanced eosinophil recruitment, and greater IL-4 and IL-13 production in a feed-forward loop. This molecular amplification is measurable as elevated total serum IgE — the circulating antibody class responsible for immediate hypersensitivity reactions — and manifests clinically as increased susceptibility to atopic dermatitis, asthma, allergic rhinitis, and, through a separate mechanism, eosinophilic esophagitis.

The Evidence

The functional and clinical significance of the rs167769/rs324011 haplotype was established in a Taiwanese pediatric cohort by Lee et al. 2015³³ Lee et al. 2015
Taiwan Children Health Study; genotyped STAT6 variants in childhood atopic dermatitis; J Dermatol Sci 2015, which showed the combined two-SNP haplotype was significantly associated with childhood atopic dermatitis at global p=0.0018 — a stronger signal than either variant alone. rs167769 individually showed borderline significance (OR 1.21, 95% CI 0.99–1.49), consistent with its role as a haplotype component rather than an independent major-effect variant.

An important additional phenotype emerged from work on eczema herpeticum (EH) — a dangerous disseminated herpes simplex virus infection that occurs predominantly in atopic dermatitis patients with barrier defects and skewed Th2 immunity. Howell et al. 2011⁴⁴ Howell et al. 2011
J Allergy Clin Immunol; 444 white AD patients genotyped for 10 STAT6 SNPs; studied susceptibility to disseminated viral skin infections found that rs167769 C allele was significantly protective against eczema herpeticum (OR 0.65, 95% CI 0.43–0.98, p=0.027), meaning T allele carriers have elevated risk for this viral complication on top of atopic dermatitis. The strongest STAT6 signal in that study involved a 2-SNP haplotype including rs167769 (24.9% frequency in EH cases vs 9.2% in controls, P=5.17×10⁻⁶), indicating the variant plays a mechanistic role in the impaired antiviral immunity associated with STAT6 overexpression.

In pediatric gastroenterology, Mougey et al. 2021⁵⁵ Mougey et al. 2021
Clin Gastroenterol Hepatol; 73 children with EoE on PPI maintenance therapy found that rs167769 (in high linkage disequilibrium with rs324011 and rs12368672, r²≥0.8) conferred a 2.3- to 2.8-fold increased odds of eosinophilic esophagitis relapse after one year of reduced-dose proton pump inhibitor maintenance. This suggests the STAT6 haplotype is a pharmacogenomic marker for EoE treatment durability.

Practical Implications

For T allele carriers, the elevated STAT6 expression lowers the threshold for Th2 immune activation. Total serum IgE — the most accessible clinical readout of Th2 axis activity — can quantify how active this pathway is and how it responds to interventions. For individuals with confirmed atopic dermatitis, the rs167769-T genotype adds genetic context to the elevated STAT6 tone identified by rs324011-T, reinforcing the biological case for IL-4/IL-13 pathway-directed therapy with dupilumab when disease is moderate to severe.

In eosinophilic esophagitis, T allele carriers who respond initially to PPI therapy should be aware that their STAT6 haplotype is associated with higher relapse rates — this finding supports closer follow-up, consideration of higher PPI maintenance dosing, or earlier escalation to IL-4/IL-13-targeted therapy (dupilumab is FDA-approved for EoE).

The eczema herpeticum data are particularly actionable: T allele carriers with active atopic dermatitis should ensure they have a clear plan for early antiviral treatment (oral acyclovir or valacyclovir) if a disseminated vesicular eruption develops. Prompt antiviral initiation substantially reduces the severity and complications of eczema herpeticum.

Interactions

rs167769 and rs324011 operate in the same functional haplotype block; individuals carrying T alleles at both loci have the highest STAT6 expression of any genotype combination. The combined haplotype interacts additively with downstream pathway variants: IL-13 rs20541-A (hyperactive IL-13 protein) and IL-4Rα rs1801275-G (sensitized receptor) both amplify the same Th2 signaling cascade that elevated STAT6 expression executes. The IL-13 promoter variant rs1800925 is an additional upstream modulator of the same pathway.

About 3 million years ago, a 900-kilobase inversion occurred on chromosome 17q21¹¹ a 900-kilobase inversion occurred on chromosome 17q21
This inversion created two distinct haplotype clades that have been recombinationally suppressed since, accumulating independent sequence variations, creating two distinct evolutionary lineages of the microtubule-associated protein tau (MAPT) gene: H1 and H2. This SNP, rs17649553, is one of several markers that can distinguish between these two haplotypes, which have profoundly different effects on the risk of developing neurodegenerative diseases involving abnormal tau protein deposits.

The MAPT gene encodes tau, a protein primarily expressed in neurons that stabilizes microtubules and supports axonal transport²² stabilizes microtubules and supports axonal transport
Microtubules are the cell's internal transportation system, and tau helps maintain their structure. When tau becomes abnormally phosphorylated and aggregates, it forms neurofibrillary tangles — pathological hallmarks of tauopathies including Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease, and some forms of Parkinson's disease and frontotemporal dementia (FTD).

The Haplotype Structure

Because of the ancient inversion, H1 and H2 exist in complete linkage disequilibrium across nearly 900kb³³ H1 and H2 exist in complete linkage disequilibrium across nearly 900kb
Any SNP in this region can tag the haplotype, as recombination between them has been suppressed for millions of years. The H1 haplotype is evolutionarily dynamic and contains numerous subhaplotypes (H1a, H1b, H1c, etc.), while H2 is more homogeneous. Population distribution is striking: H2 is rare in Africans, almost absent in East Asians, but found at approximately 20% frequency in Europeans⁴⁴ H2 is rare in Africans, almost absent in East Asians, but found at approximately 20% frequency in Europeans
This population-specific distribution suggests selection pressure in European populations.

The Evidence for Parkinson Disease

A 2007 study of 1,762 Parkinson's disease patients and 2,010 controls found a robust association between the H1/H1 diplotype and PD risk (OR 1.46, 95% CI 1.25-1.69, p = 8×10⁻⁷)⁵⁵ A 2007 study of 1,762 Parkinson's disease patients and 2,010 controls found a robust association between the H1/H1 diplotype and PD risk (OR 1.46, 95% CI 1.25-1.69, p = 8×10⁻⁷)
The effect was evident in both familial and sporadic subgroups, men and women, and early- and late-onset disease. A meta-analysis of 23 Caucasian case-control series (7,736 patients, 9,339 controls) estimated an overall OR of 0.78 for H2 versus H1⁶⁶ A meta-analysis of 23 Caucasian case-control series (7,736 patients, 9,339 controls) estimated an overall OR of 0.78 for H2 versus H1
This suggests H2 may be protective against Parkinson's disease.

Progressive Supranuclear Palsy and Other 4R Tauopathies

The association is even stronger for PSP. The H1 haplotype is found in approximately 94% of PSP patients compared to around 78% in healthy adults⁷⁷ The H1 haplotype is found in approximately 94% of PSP patients compared to around 78% in healthy adults
Nearly all PSP patients are H1 homozygotes, though H1 appears necessary but not sufficient to cause disease. PSP is a rare atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy, unprovoked falls, axial rigidity, and cognitive decline, with predominant accumulation of 4-repeat tau in neurons and glia⁸⁸ with predominant accumulation of 4-repeat tau in neurons and glia
The 4R:3R tau isoform ratio appears critical in PSP pathogenesis.

Corticobasal degeneration and Alzheimer's disease also show H1 associations, though the specific subhaplotypes involved differ. The H1c subhaplotype, tagged by rs242557, is specifically associated with increased Alzheimer's disease risk in APOE ε4 non-carriers⁹⁹ The H1c subhaplotype, tagged by rs242557, is specifically associated with increased Alzheimer's disease risk in APOE ε4 non-carriers
Different H1 subhaplotypes confer risk for different tauopathies.

The Pick's Disease Paradox

In a striking reversal, a 2024 study of 338 pathologically confirmed Pick's disease cases found the H2 haplotype associated with increased risk¹⁰¹⁰ a 2024 study of 338 pathologically confirmed Pick's disease cases found the H2 haplotype associated with increased risk
This is opposite to the protective effect seen in PSP and CBD. Pick's disease is a 3-repeat tauopathy characterized by Pick bodies in the frontal and temporal lobes. This finding suggests the H1/H2 polymorphism may affect the balance of 3R and 4R tau isoforms through alternative splicing of exon 10¹¹¹¹ the H1/H2 polymorphism may affect the balance of 3R and 4R tau isoforms through alternative splicing of exon 10
H1 may promote 4R tau, while H2 may favor 3R tau.

Frontotemporal Dementia

The majority of genetic FTD is caused by mutations in C9ORF72, MAPT, or GRN genes¹²¹² The majority of genetic FTD is caused by mutations in C9ORF72, MAPT, or GRN genes
About 10-20% of all FTD cases are genetic. While pathogenic mutations in MAPT cause familial FTD with autosomal dominant inheritance, the common H1 haplotype also contributes to sporadic FTD risk, particularly the H1c subclade¹³¹³ the common H1 haplotype also contributes to sporadic FTD risk, particularly the H1c subclade
A 2024 GWAS of 4,685 sporadic FTD cases found genome-wide significant association at the MAPT locus (p = 2.5×10⁻¹²).

Mechanism and Splicing

Studies using whole-locus genomic MAPT expression vectors demonstrate that intronic variants like rs1800547 and rs17651213 regulate haplotype-specific splicing of exon 3¹⁴¹⁴ Studies using whole-locus genomic MAPT expression vectors demonstrate that intronic variants like rs1800547 and rs17651213 regulate haplotype-specific splicing of exon 3
The splicing factors hnRNP F and hnRNP Q mediate this haplotype-specific regulation. The H2 haplotype is associated with lower total MAPT expression and altered isoform ratios compared to H1¹⁵¹⁵ The H2 haplotype is associated with lower total MAPT expression and altered isoform ratios compared to H1
This may explain the differential tauopathy risk profiles. Specifically, H1 appears to favor production of 4R tau isoforms, which may explain its association with 4R tauopathies like PSP and CBD.

Aging and Bradykinesia

Even in neurologically healthy older adults, the H2 haplotype is associated with age-related motor impairment, particularly bradykinesia (slowness of movement)¹⁶¹⁶ the H2 haplotype is associated with age-related motor impairment, particularly bradykinesia (slowness of movement)
This suggests MAPT variants influence aging-related functional decline independent of clinical disease. The mechanism appears distinct from classical Parkinson's disease and may involve cortico-nigro-striatal pathways different from those typically affected in PD.

Interactions

The H1/H2 haplotype interacts with other genetic risk factors. In Huntington's disease (a secondary tauopathy), H2 carriers show more rapid cognitive decline compared to H1 carriers¹⁷¹⁷ H2 carriers show more rapid cognitive decline compared to H1 carriers
This suggests tau pathology contributes to HD progression. In APOE ε4 non-carriers, the MAPT H1 haplotype becomes a more prominent risk factor for Alzheimer's disease¹⁸¹⁸ In APOE ε4 non-carriers, the MAPT H1 haplotype becomes a more prominent risk factor for Alzheimer's disease
This suggests genetic interactions between the two major AD risk loci.

The relationship between MAPT haplotypes and alpha-synuclein pathology (the hallmark of Parkinson's disease) remains incompletely understood, though interaction analyses have not found evidence of epistatic effects between SNCA and MAPT loci¹⁹¹⁹ interaction analyses have not found evidence of epistatic effects between SNCA and MAPT loci
The two risk factors appear to act independently.